Market Research Report
North America Crispr Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||410547|
|Published||Content info||102 Pages
Delivery time: 1-2 business days
|North America Crispr Market Forecast 2019-2027|
|Published: December 10, 2018||Content info: 102 Pages||
Over the forecast period of 2019-2027, the North America CRISPR market is projected to witness a CAGR of 31.97% accounting for the highest revenue share, as compared to other regional markets.
Pharmaceutical industries are the key end-users of the CRISPRs in this region. Also, the growing market for stem cell therapy is considerably fueling the demand for the CRISPR market. Increasing grant for orphan drug status for stem cell therapeutics by the FDA, an extensive government funding and the presence of major leading market companies in the region are some of the important factors propelling the growth of this market. The US is considered to be a lucrative market in this region, driven by increased healthcare spending. The Canadian Budget 2016, too, played a significant role in the development of CRISPR market in the region by funding various research activities of genomics, drug discovery and stem cell research.
Noted players in this market include Crispr Therapeutics Ag, Novartis International Ag, Integrated DNA Technologies (IDT), Editas Medicine, Genscript, Cellectis Bioresearch Sas, Precision Biosciences, Transposagen Biopharmaceuticals Inc, Sigma-Aldrich (Merck), Intellia Therapeutics Inc, and Origene Technologies Inc.